A Score for Predicting @entity955 in @entity64 XXXX : iPAB Score.

@entity1 @entity64 @entity384 @entity3876 @entity955 @entity943 @entity385
BACKGROUND: Detection of paroxysmal @entity955 (PAF) after a @entity64 is challenging. The purpose of this study was to develop a clinical score to predict PAF in a cohort of acute @entity385 @entity1 prospectively and to validate it in an independent cohort. METHODS: Consecutive acute @entity385 @entity1 without permanent @entity955 were enrolled in a derivation sample (n  =  294) or a validation sample (n  =  155). We developed a score for predicting PAF by independent risk factors derived from a logistic regression analysis of the derivation cohort and validated the score in the external cohort. RESULTS: Multivariate analysis in the derivation cohort identified 3 variables independently associated with PAF. We calculated a score from these variables (history of @entity943 or antiarrhythmic agent use [yes, 3 points], left @entity384 [>= 40  mm, 1 point], brain natriuretic peptide [ @entity3876 , >= 50 pg/mL, 1 point; >= 90 pg/mL, 2 points; >= 150 pg/ml, 3 points], total score, 0-7). The iPAB score (identified by past history of @entity943 or antiarrhythmic agent use, @entity384 , and @entity3876 elevation) predicted PAF in the derivation (c statistic, .90) and validation (.94) cohorts at levels statistically superior to other biomarkers and clinical scores. For a total score 2 or more, the sensitivity and specificity were 93% and 71%, respectively. For a total score of 4 or more, the corresponding values were 60% and 95%. CONCLUSIONS: Our prospective study suggests that this simple risk score superior to other scores help clinicians predict PAF or identify good candidates for further evaluation to detect PAF.
